Etranacogene Dezaparvovec: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Etranacogene Dezaparvovec. Educational only — not medical advice.
Labeled uses
HEMGENIX is indicated for treatment of adults with Hemophilia B (congenital Factor IX deficiency) who: Currently use Factor IX prophylaxis therapy, or Have current or historical life-threatening hemorrhage, or Have repeated, serious spontaneous bleeding episodes.
Source: FDA labeling via NIH DailyMed (set 35b2db65…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.